About us

Message from the CEO

Antibodies are responsible for the immune responses in animals, which protect them from foreign substances such as bacteria and viruses. Currently, antibodies are widely used as therapeutic and diagnostic agents for cancer, autoimmune diseases, and infectious diseases like COVID-19. Antibodies play an important role in healthy living, and their role is expected to develop further in the future.
iBody is a start-up company from the Nagoya University of Japan, specializing in antibody mining technology. Our unique “Ecobody” technology enables us to obtain useful antibodies rapidly and efficiently from rabbits and humans, thereby producing antibodies with excellent properties necessary for diagnostics/reagents and therapeutic agents.
With this “Ecobody” technology, we will contribute to the development of diagnostics and therapeutics and human health by generating antibodies that are difficult to generate through conventional technologies.

Yo Amakusa

Company Information

Our missionContributing to the development of diagnostics and therapeutics using innovative antibody exploration technology.

VisionWe are the only antibody company worldwide that accelerates
innovation and continues to deliver antibodies that are difficult to obtain with other technologies.

iBody logo
Company Name iBody Inc.
Headquarters 〒464-0858
Nagoya Life Science Incubator (NALIC) #417
2-22-8, Chikusa, Chikusa-ku, Nagoya, 464-0858, Japan
Foundation February 2018
Representative Yo Amakusa, CEO
Business Monoclonal antibody generating service/Collaborative research
Discovery and development of novel antibody therapeutics

iBody is a member company of J-Startup CENTRAL

About J-Startup CENTRAL

Management Team

Yo Amakusa, MBA

Yo Amakusa, MBA CEO

Yo Amakusa had substantial experiences in business development, product management and commercial at Sumitomo Pharma. He joined Ambicion which is a start-up company from RIKEN and led the business strategy as an executive officer. He became CEO of iBody from March 2020.

Shoji Ohuchi, Ph.D.

Shoji Ohuchi, Ph.D. CSO

Shoji Ohuchi received Ph.D. in Chemistry and worked in drug discovery in academia. He also served as a biotech advisor. After that, he gained experience as a senior scientist at domestic and international academic institutions. He became CSO of iBody from April 2018. He became CSO and CTO from April 2023.

Scientific Advisors

Yoshihiro Kakeji, MD, Ph.D. / Professor, Graduate School of Medicine, Kobe University

Kouhei Tsumoto, Ph.D. / Professor, Graduate School of Engineering, The University of Tokyo

Hideo Nakano, Ph.D. / Graduate School of Bioagricultural Sciences, Nagoya University

Hiromune Ando, Ph.D/ Professor, Institute for Glyco-core Research, Gifu University